Adjunctive therapy in Parkinson’s disease: the role of rasagiline

References

• Parkinson.org [homepage on the Internet]OberdorfJSchmidtPImproving care for people with Parkinson’s diseaseNational Parkinson Foundation22010 Available from: http://www.parkinson.org/NationalParkinsonFoundation/files/c2/c2abb799-4e2b-41c5-8c06-47-f3424a58d0.pdfAccessed February 6, 2012
   Google Scholar
• ParkinsonJAn essay on the shaking palsy. 1817J Neuropsychiatry Clin Neurosci200214222323611983801
   PubMed Web of Science ®Google Scholar
• HaasLFJean Martin Charcot 1825–1893 and Jean Baptiste Charcot 1867–1936J Neurol Neurosurg Psychiatry200171452411561039
   PubMedGoogle Scholar
• SiderowfASternMUpdate on Parkinson diseaseAnn Intern Med2003138865165812693888
   PubMed Web of Science ®Google Scholar
• SuchowerskyOReichSPerlmutterJPractice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of NeurologyNeurology200666796897516606907
   PubMed Web of Science ®Google Scholar
• HughesAJDanielSEKilfordLLeesAJAccuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinicopathological study of 100 casesJ Neurol Neurosurg Psychiatry19925531811841564476
   PubMed Web of Science ®Google Scholar
• ZesiewiczTHauserRMedical treatment of motor and nonmotor features of Parkinson’s diseaseContinuum20071311238
   Google Scholar
• MiyasakiJMShannonKVoonVPractice parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review) Report of the Quality Standards of Subcommittee of the American Academy of NeurologyContinuum2007131193201
   Google Scholar
• BraakHBohlJMullerCStanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson’s disease reconsideredMov Disord200621122042205117078043
   PubMed Web of Science ®Google Scholar
• FornoLSConcentric hyaline intraneuronal inclusions of Lewy type in the brains of elderly persons (50 incidental cases): relationship to parkinsonismJ Am Geriatr Soc19691765575754182529
   PubMed Web of Science ®Google Scholar
• IshiyamaMYagishitaSHasegawaKYokoyamaTUltrastructural study (transmission and scanning EM) of cortical Lewy bodiesNeuropathology2006262A58
   Google Scholar
• BraakHDel TrediciKRubUde VosRAJansen SteurENBraakEStaging of brain pathology related to sporadic Parkinson’s diseaseNeurobiol Aging200324219721112498954
   PubMed Web of Science ®Google Scholar
• KincsesZTVecseiLPharmacological therapy in Parkinson’s disease: focus on neuroprotectionCNS Neurosci Ther201117534536720438581
   PubMed Web of Science ®Google Scholar
• BogaertsVTheunsJvan BroeckhovenCGenetic f indings in Parkinson’s disease and translation into treatment: a leading role for mitochondria?Genes Brain Behav20087212915117680806
   PubMed Web of Science ®Google Scholar
• MakerHSWeissCSilidesDJCohenGCoupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenatesJ Neurochem19813625895937463078
   PubMed Web of Science ®Google Scholar
• GerlachMRiedererPPrzuntekHYoudimMBMPTP mechanisms of neurotoxicity and their implications for Parkinson’s diseaseEur J Pharmacol199120842732861815982
   PubMed Web of Science ®Google Scholar
• LangstonJWBallardPTetrudJWIrwinIChronic parkinsonism in humans due to a product of meperidine-analog synthesisScience198321945879799806823561
   PubMed Web of Science ®Google Scholar
• McGeerPLItagakiSBoyesBEMcGeerEGReactive microglias are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brainsNeurology1988388128512913399080
   PubMed Web of Science ®Google Scholar
• ImamuraKHishikawaNSawadaMNagatsuTYoshidaMHashizumeYDistribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson’s disease brainsActa Neuropathol (Berl)2003106651852614513261
   PubMed Web of Science ®Google Scholar
• MirzaBHadbergHThomsenPMoosTThe absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson’s diseaseNeuroscience200095242543210658622
   PubMed Web of Science ®Google Scholar
• MogiMHaradaMNarabayashiHInagakiHMinamiMNagatsuTInterleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson’s diseaseNeurosci Lett1996211113168809836
   PubMed Web of Science ®Google Scholar
• MogiMHaradaMKondoTRiedererPNagatsuTInterleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain. Short communicationJ Neural Transm19961038–9107710819013395
   PubMed Web of Science ®Google Scholar
• MogiMHaradaMKondoTNarabayashiHRiedererPNagatsuTTransforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson’s diseaseNeurosci Lett199519321291327478158
   PubMed Web of Science ®Google Scholar
• MogiMHaradaMKondoTRiedererPNagatsuTBrain beta 2-microglobulin levels are elevated in the striatum in Parkinson’s diseaseJ Neural Transm Park Dis Dement Sect19959187927605592
   PubMedGoogle Scholar
• MogiMHaradaMKondoTInterleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patientsNeurosci Lett199418021471507700568
   PubMed Web of Science ®Google Scholar
• MogiMHaradaMRiedererPNarabayashiHFujitaKNagatsuTTumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patientsNeurosci Lett19941651–22082108015728
   PubMed Web of Science ®Google Scholar
• MogiMHaradaMKojimaKBeta 2-microglobulin decrease in cerebrospinal fluid from parkinsonian patientsNeurosci Lett19891041–22412462682394
   PubMed Web of Science ®Google Scholar
• GerhardAPaveseNHottonGIn vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s diseaseNeurobiol Dis200621240441216182554
   PubMed Web of Science ®Google Scholar
• OuchiYYoshikawaESekineYMicroglial activation and dopamine terminal loss in early Parkinson’s diseaseAnn Neurol200557216817515668962
   PubMed Web of Science ®Google Scholar
• ChauKYChingHLSchapiraAHCooperJMRelationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinson’s disease pathogenesisJ Neurochem200911031005101319493164
   PubMed Web of Science ®Google Scholar
• OlanowCWPrusinerSBIs Parkinson’s disease a prion disorder?Proc Natl Acad Sci U S A200910631125711257219666621
   PubMed Web of Science ®Google Scholar
• BonciAGrillnerPMercuriNBBernardiGL-Type calcium channels mediate a slow excitatory synaptic transmission in rat midbrain dopaminergic neuronsJ Neurosci19981817669367039712641
   PubMed Web of Science ®Google Scholar
• PingHXShepardPDApamin-sensitive Ca(2+)-activated K+ channels regulate pacemaker activity in nigral dopamine neuronsNeuroreport1996738098148733751
   PubMed Web of Science ®Google Scholar
• RodriguezMCObesoJAOlanowCWSubthalamic nucleus-mediated excitotoxicity in Parkinson’s disease: a target for neuroprotectionAnn Neurol1998443 Suppl 1S175S1889749591
   PubMed Web of Science ®Google Scholar
• DingledineRBorgesKBowieDTraynelisSFThe glutamate receptor ion channelsPharmacol Rev199951176110049997
   PubMed Web of Science ®Google Scholar
• GreenamyreJTPorterRHAnatomy and physiology of glutamate in the CNSNeurology19944411 Suppl 88S7S137526272
   PubMed Web of Science ®Google Scholar
• HetzCAER stress signaling and the BCL-2 family of proteins: from adaptation to irreversible cellular damageAntioxid Redox Signal20079122345235517854276
   PubMed Web of Science ®Google Scholar
• LindholmDWootzHKorhonenLER stress and neurodegenerative diseasesCell Death Differ200613338539216397584
   PubMed Web of Science ®Google Scholar
• GheorghiadeMKonstamMABurnettJCJrShort-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status TrialsJAMA2007297121332134317384438
   PubMed Web of Science ®Google Scholar
• KerrJFWyllieAHCurrieARApoptosis: a basic biological phenomenon with wide-ranging implications in tissue kineticsBr J Cancer19722642392574561027
   PubMed Web of Science ®Google Scholar
• HirschECHunotSNeuroinflammation in Parkinson’s disease: a target for neuroprotection?Lancet Neurol20098438239719296921
   PubMed Web of Science ®Google Scholar
• FerrerIBlancoRCutillasBAmbrosioSFas and Fas-L expression in Huntington’s disease and Parkinson’s diseaseNeuropathol Appl Neurobiol200026542443311054182
   PubMed Web of Science ®Google Scholar
• HuotPParentADopaminergic neurons intrinsic to the striatumJ Neurochem200710161441144717286588
   PubMed Web of Science ®Google Scholar
• KitahamaKGeffardMAranedaSLocalization of L-DOPA uptake and decarboxylating neuronal structures in the cat brain using dopamine immunohistochemistryBrain Res20071167567017692830
   PubMed Web of Science ®Google Scholar
• YamadaHAimiYNagatsuITakiKKudoMAraiRImmunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model ratsNeurosci Res20075911717586078
   PubMed Web of Science ®Google Scholar
• FahnSthe Parkinson Study GroupDoes levodopa slow or hasten the rate of progression of Parkinson’s disease?J Neurol2005252Suppl 4IV37IV4216222436
   PubMedGoogle Scholar
• RajputAHUittiRRajputATimely levodopa (LD) administration prolongs survival in Parkinson’s diseaseParkinsonism Relat Disord19973315916518591070
   PubMedGoogle Scholar
• ZesiewiczTSullivanKHauserRLevodopa-induced dyskinesia in Parkinson’s disease: epidemiology, etiology and treatmentCurr Neurol Neurosci Rep20077430231017618536
   PubMed Web of Science ®Google Scholar
• DostertPLStrolin BenedettiMTiptonKFInteractions of monoamine oxidase with substrates and inhibitorsMed Res Rev19899145892644497
   PubMed Web of Science ®Google Scholar
• BirkmayerWRiedererPYoudimMBHLinauerWThe potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, DeprenylJ Neural Trans1975363–4303326
   PubMed Web of Science ®Google Scholar
• KalirASabbaghAYoudimMBHSelective acetylenic ‘suicide’ and reversible inhibitors of monoamine oxidase types A and BBr J Pharmacol198173155647284698
   PubMed Web of Science ®Google Scholar
• SandlerMGloverVAshfordASternGMAbsence of “cheese effect” during deprenyl therapy: some recent studiesJ Neural Trans1978433–4209215
   Web of Science ®Google Scholar
• ElsworthJDGloverVReynoldsGPDeprenyl administration in man: a selective monoamine oxidase B inhibitor without the ‘cheese effect’Psychopharmacology1978571333896466
   PubMed Web of Science ®Google Scholar
• LeesAJKohoutLJShawKMDeprenyl in Parkinson’s diseaseLancet19973108042791795
   Google Scholar
• Parkinson Study GroupDATATOP: a multicenter controlled clinical trial in early Parkinson’s diseaseArch Neurol19894610105210602508608
   PubMedGoogle Scholar
• LeWittPANeuroprotection by anti-oxidant strategies in Parkinson’s diseaseEur Neurol199333Suppl 124308375428
   PubMed Web of Science ®Google Scholar
• ShoulsonIDATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl and tocopherol antioxidative therapy of parkinsonism1998Ann Neurol443 Suppl 1S160S1669749589
   PubMed Web of Science ®Google Scholar
• MahmoodIClinical pharmacokinetics and pharmacodynamics of selegiline. An updateClin Pharmacokinet1997332911029260033
   PubMed Web of Science ®Google Scholar
• ShinHSMetabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolitesDrug Metab Dispos19972566576629193866
   PubMed Web of Science ®Google Scholar
• Bar AmOAmitTYoudimMBContrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegilineNeurosci Lett2004355316917214732458
   PubMed Web of Science ®Google Scholar
• BindaCHubalekFLiMCrystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan classJ Med Chem20044771767177415027868
   PubMed Web of Science ®Google Scholar
• MaruyamaWNaoiMNeuroprotection by (−)-deprenyl and related compoundsMech Ageing Dev19991112–318920010656536
   PubMed Web of Science ®Google Scholar
• Bar-AmOWeinrebOAmitTYoudimMBRegulation of Bcl-2 family proteins, neuroprotective factors, and APP processing in the neurorescue activity of propargylamineFASEB J200519131899190116148027
   PubMed Web of Science ®Google Scholar
• MurerMGYanQRaisman-VozariRBrain-derived neurotrophic factor in the control human brain and in Alzheimer’s disease and Parkinson’s diseaseProg Neurobiol20016317112411040419
   PubMed Web of Science ®Google Scholar
• WangLMuramatsuSLuYDelayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson’s diseaseGene Ther20029638138911960314
   PubMed Web of Science ®Google Scholar
• MandelSWeinrebOAmitTYoudimMBMechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivativesBrain Res Brain Res Rev200548237938715850677
   PubMedGoogle Scholar
• MaruyamaWAkaoYCarrilloMCKitaniKYoudimMBNaoiMNeuroprotection by propargylamines in Parkinson’s disease: suppression of apoptosis and induction of prosurvival genesNeurotoxicol Teratol200224567568212200198
   PubMed Web of Science ®Google Scholar
• CarrilloMCMinamiCKitaniKEnhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the ratLife Sci200067557758510993123
   PubMed Web of Science ®Google Scholar
• AkaoYMaruyamaWShimizuSMitochondrial permeability transition mediates apoptosis induced by N-methyl(R) salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindanJ Neurochem200282491392312358797
   PubMed Web of Science ®Google Scholar
• YoudimMBAmitTFalach-YogevMBar AmOMaruyamaWNaoiMThe essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagilineBiochem Pharmacol20036681635164114555244
   PubMed Web of Science ®Google Scholar
• MaruyamaWAkaoYYoudimMBDavisBANaoiMTransfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinolJ Neurochem200178472773511520893
   PubMed Web of Science ®Google Scholar
• WeinrebOBar-AmOAmitTChillag-TalmorOYoudimMBNeuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family membersFASEB J200418121471147315247150
   PubMed Web of Science ®Google Scholar
• RabeyJMSagiIHubermanMRasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson’s disease: a doubleblind study as adjunctive therapy to levodopaClin Neuropharmacol200023632433011575866
   PubMed Web of Science ®Google Scholar
• SternMBMarekKLFriedmanJDouble-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson’s disease patientsMov Disord200419891692315300656
   PubMed Web of Science ®Google Scholar
• FreedmanNMMishaniEKrauszYIn vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PETJ Nucl Med200546101618162416204711
   PubMed Web of Science ®Google Scholar
• KupschASautterJGotzMEMonoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegilineJ Neural Transm20011088–9985100911716151
   PubMed Web of Science ®Google Scholar
• HeikkilaREDuvoisinRCFinbergJPYoudimMBPrevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-BEur J Pharmacol198511633133173935467
   PubMed Web of Science ®Google Scholar
• OlanowCWRascolOHauserRA double-blind, delayedstart trial of rasagiline in Parkinson’s diseaseN Engl J Med2009361131268127819776408
   PubMed Web of Science ®Google Scholar
• HurleyDFDA committee: Rasagiline rejected as ‘disease modifying’ for Parkinson Disease20111121167
   Google Scholar
• Parkinson Study GroupA controlled trial of rasagiline in early Parkinson disease: the TEMPO StudyArch Neurol200259121937194312470183
   PubMed Web of Science ®Google Scholar
• Parkinson Study GroupA controlled, randomized, delayedstart study of rasagiline in early Parkinson diseaseArch Neurol200461456156615096406
   PubMed Web of Science ®Google Scholar
• FahnSOakesDShoulsonILevodopa and the progression of Parkinson’s diseaseN Engl J Med2004351242498250815590952
   PubMed Web of Science ®Google Scholar
• HauserRLewMHurtigHOndoWWojcieszekJEarly treatment with rasagiline is more beneficial than delayed treatment start in the long-term management of Parkinson’s disease: P251Mov Disord200520S75
   Web of Science ®Google Scholar
• Parkinson Study GroupEffect of lazabemide on the progression of disability in early Parkinson’s diseaseAnn Neurol1996401991078687199
   PubMed Web of Science ®Google Scholar
• ShultsCWOakesDKieburtzKEffects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional declineArch Neurol200259101541155012374491
   PubMed Web of Science ®Google Scholar
• RascolOBrooksDJMelamedERasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomized, double-blind, parallel-group trialLancet2005365946394795415766996
   PubMed Web of Science ®Google Scholar
• Parkinson Study GroupA randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO studyArch Neurol200562224124815710852
   PubMed Web of Science ®Google Scholar
• MontastrucJLChaumerliacCDesboeufKAdverse drug reactions to selegiline: a review of the French pharmacovigilance databaseClin Neuropharmacol200023527127511154095
   PubMed Web of Science ®Google Scholar
• AbassiZABinahOYoudimMBCardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegilineBr J Pharmacol2004143337137815339864
   PubMed Web of Science ®Google Scholar
• GoetzCGSchwidSEberlySSafety of rasagiline in elderly patients with Parkinson diseaseNeurology2006661427142916682679
   PubMed Web of Science ®Google Scholar
• Da PradaMZurcherGWuthrichIHaefelyWEOn tyramine, food, beverages and the reversible MAO inhibitor moclobemideJ Neural Transm Suppl19882631563283290
   PubMedGoogle Scholar
• Parkinson Study GroupTyramine challenge to assess the safety of rasagiline monotherapy in a placebo-controlled multicenter trial for early Parkinson’s disease (the TEMPO Study)Neurology200156Suppl 3A345
   Google Scholar
• ZornbergGLBodkinJACohenBMSevere adverse interaction between pethidine and selegilineLancet199133787352461670882
   PubMed Web of Science ®Google Scholar
• ChenJJLyAVRasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson’s diseaseAm J Health Syst Pharm2006631091592816675649
   PubMed Web of Science ®Google Scholar
• Azilect.com [homepage on the Internet]Anti-depressant chart reviewTeva Neuroscience, Inc2010 Available from: http://www.azilect.com/HCP/Tools-Resources/Anti-Depressant-Fact-Card.aspxAccessed February 13, 2012
   Google Scholar
• ChenJJSwopeDMClinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson diseaseJ Clin Pharmacol200545887889416027398
   PubMed Web of Science ®Google Scholar
• Azilect.com [homepage on the Internet]Azilect dosage: Parkinson’s disease medication dosingTeva Neuroscience2010 Available from: http://www.azilect.com/HCP/Azilect-Therapy/Dosing.aspxAccessed February 13, 2012
   Google Scholar
• HanagasiHAGurvitHUnsalanPThe effects of rasagiline on cognitive deficits in Parkinson’s disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter studyMov Disord201126101851185821500280
   PubMed Web of Science ®Google Scholar
• HudryJRinneJOKeranenTEckertLCochranJMCost-utility model of rasagiline in the treatment of advanced Parkinson’s disease in FinlandAnn Pharmacother200640465165716569799
   PubMed Web of Science ®Google Scholar